Table 3.

H-1PV-induced suppression of human tumor xenografts in mouse models.

Tumor entity (tumor model)	H-1PV-induced anti-tumor effects	Reference
Breast carcinoma (HMEC HBL100 cells s.c. implanted in nude mice)	Tumor growth suppression and complete remission with no recurrence in 50% of the virus-treated animals	Dupressoir et al. (1989)
Cervical carcinoma (HeLa cells s.c. implanted in SCID mice)	Complete tumor regression after high virus dose application	Faisst et al. (1998)
Burkitt lymphoma (Namalwa cells s.c. implanted in SCID mice)	Efficient tumor regression and necrosis. Virus-induced effects also after application at late disease stages	Angelova et al. (2009a)
Gastric carcinoma (SGC-7901 cells or MKN28, SGC7901, MKN45 cells transfected with NS1-expressing plasmid, s.c. implanted in nude mice)	Tumor growth suppression by in vivo virus infection or ex vivo NS1 transduction	Zhang et al. (1997) and Wang et al. (2012)
Pancreatic carcinomaa (human BxPC-3 cells s.c. implanted in nude mice; PDAC operational material s.c. implanted in SCID mice)	H-1PV dose-dependent tumor growth delay	Angelova et al. (2009b) and Li et al. (2013)

^aImplantation of non-established (patient-derived) tumor material.

HMEC, human mammary epithelial cells; s.c., subcutaneously; PDAC, pancreatic ductal adenocarcinoma.